Shree Ganesh Remedies Ltd.
Snapshot View

402.05 +0.15 ▲0.0%

02 August 2021, 04:00:00 P.M.
Volume: 5,663

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.ganeshremedies.com
Financial Indicators
Market Cap 402.26 Cr.
Earnings per share (EPS) 9.75 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 41.24 Trailing Twelve Months Ending 2021-03
Industry PE 32.66 Trailing Twelve Months Ending 2021-03
Book Value / Share 52.31 Trailing Twelve Months Ending 2021-03
Price to Book Value 7.69 Calculated using Price: 402.00
Dividend Yield 0.37 Period Ending 2020-03
No. of Shares Subscribed 1.00 Cr. 10,006,446 Shares
FaceValue 10
Company Profile

The company was originally incorporated as “Shree Ganesh Remedies Private Limited” at Ahmedabad, Gujarat as a Private Limited Company under the provisions of Companies Act, 1956 vide Certificate of Incorporation dated April 27, 1995 bearing registration number 025661 issued by Assistant Registrar of Companies, Gujarat, Dadra & Nagar Haveli. Subsequently, the company was converted into a Public Limited Company pursuant to special resolution passed by the shareholders at the Extraordinary General Meeting held on July 12, 2017 and fresh certificate of incorporation consequently upon change of name was issued by Registrar of Companies, Gujarat, Ahmedabad dated July 28, 2017 and name of the company was changed to “Shree Ganesh Remedies Limited”.

The manufacturing process is supported by Total Quality Management techniques and is supervised through various quality control equipments and qualified personnel. The products are manufactured for export market and also for domestic and foreign markets. It entered the International market in the year 2006 and are on regular basis exporting its products to various countries. The company’s manufacturing facility is divided into three manufacturing plants namely Plant I, II and III spread across 9715 square meters having different product manufacturing capabilities and process.

Business area of the company

The company is as ISO 9001:2015, ISO 14001:2015 BS and OHSAS 18001:2007 certified company and is engaged in manufacturing and dispatch of drug intermediates and chemicals like amine hydrochloride and specialty fine chemicals for pharmaceutical industry. The company manufactures products relating to antipsychotic, antiseptic, deprotonation reactions, hyperlipidemia, alzheimers and anti-viral.

Key events and milestones

  • 1995: Incorporation of the company.
  • 2011: Received ISO 9001:2015 Certification.
  • 2011: Received ISO 14001:2015 Certification.
  • 2015: Received BS OHSAS 18001:2007 Certification.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+0.04%
1 Week
-1.31%
1 Month
+3.97%
3 Month
+30.05%
6 Month
+145.00%
1 Year
+372.06%
2 Year
+566.86%
5 Year
8 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 17.57 31.98 10.38 8.06 17.31 20.75 19.95 25.35
Return on Capital Employed (%) 23.33 43.08 16.15 12.42 26.15 27.68 27.04 32.63
Return on Assets (%) 11.93 23.85 8.56 7.01 14.34 16.52 16.20 20.56

Balance Sheet View Details

Particulars 8 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 8 12 13 14 17 29 34 42
Non Curr. Liab. 1 0 0 0 0 0 1 0
Curr. Liab. 3 3 2 2 4 7 7 10
Minority Int.
Equity & Liab. 12 15 15 16 21 36 41 52
Non Curr. Assets 4 5 5 5 5 7 16 17
Curr. Assets 8 10 10 11 17 28 26 35
Misc. Exp. not W/O
Total Assets 12 15 15 16 21 36 41 52

Profit Loss View Details

Particulars 8 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 13 18 17 16 20 27 35 58
Other Income 1 1 0 0 0 2 1 4
Total Income 13 19 17 16 20 29 36 63
Total Expenditure -10 -14 -14 -14 -16 -22 -27 -47
PBIDT 3 5 3 2 5 7 10 15
Interest 0 0 0 0 0 0 0 0
Depreciation -1 -1 -1 -1 -1 -1 -1 -2
Taxation -1 -2 -1 -1 -1 -2 -2 -3
Exceptional Items
PAT 1 3 1 1 3 5 6 10

Cash Flow View Details

Particulars 8 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. -1 -5 4
Cash Fr. Inv. -3 0 -3
Cash Fr. Finan. 8 0 0
Net Change 4 -5 1
Cash & Cash Eqvt 6 1 2

Shareholding Pattern View Details

9 Qtrs 2018-03 (%) 2018-09 (%) 2019-03 (%) 2019-09 (%) 2020-03 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 62.72 62.72 62.72 62.72 63.57 63.57 63.57 68.39 68.39
Public 37.28 37.28 37.28 37.28 36.43 36.43 36.43 31.61 31.61
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Tue, 20 Jul 2021
Shareholding for the Period Ended June 30 2021
Shree Ganesh Remedies Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Wed, 14 Jul 2021
Announcement under Regulation 30 (LODR)-Newspaper Publication
Quarterly Financial Results - Newspaper Publication
Tue, 13 Jul 2021
Financial Results For The Quarter Ended On June 30 2021.
Financial Results for the Quarter ended on June 30 2021.

Technical Scans View Details

Mon, 02 Aug 2021
High Delivery Percentage High Delivery Percentage
Close Crossing Last Month Close From Below Close Crossing Last Month Close From Below
Close Within 52 Week High Zone Close Within 52 Week High Zone
5 SMA Crossing 20 SMA From Above 5 SMA Crossing 20 SMA From Above
CCI Trending Up CCI Trending Up

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 185,816.50 774.45 +0.1%
Divi's Laboratories Ltd. 130,822.92 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. 78,219.21 4,701.80 -0.2%
Cipla Ltd. 74,356.30 921.80 +0.2%
Cadila Healthcare Ltd. 60,574.85 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. 58,218.41 4,049.00 +0.4%
Piramal Enterprises Ltd. 56,317.82 2,480.15 +7.0%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 30.95 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 65.93 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.02 4,701.80 -0.2%
Cipla Ltd. Consolidated 2021-03 30.92 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 28.39 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 387.19 4,049.00 +0.4%
Piramal Enterprises Ltd. Consolidated 2021-03 42.27 2,480.15 +7.0%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.88 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 14.08 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.37 4,701.80 -0.2%
Cipla Ltd. Consolidated 2021-03 4.06 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 4.66 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.67 4,049.00 +0.4%
Piramal Enterprises Ltd. Consolidated 2021-03 1.65 2,480.15 +7.0%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 0.18 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,049.00 +0.4%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,480.15 +7.0%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 10.09 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,049.00 +0.4%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,480.15 +7.0%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 12.53 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,049.00 +0.4%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,480.15 +7.0%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,049.00 +0.4%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,480.15 +7.0%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,049.00 +0.4%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,480.15 +7.0%